Quadrivalent (influenza vaccine, adjuvanted Seqirus) for adultsĢ020) and WHO (February 1, 2020) declared public healthĮmergencies regarding 2019 novel coronavirus.ĪCIP recommendations on the use of Td and Tdap vaccines. Meningococcal disease caused by serogroups A, C, W, and Y in MenQuadfi (MenACWY) conjugate vaccine for prevention of invasive Head-and-neck cancers caused by relevant HPV types. Recommendations on the use of influenza vaccines for the 2020-2021ĪCIP recommendations on the use of hepatitis A vaccine.įor Gardasil 9 to include preventing oropharyngeal and other Recommendations on the use meningococcal vaccines. Use Authorization (EUA) for Pfizer-BioNTech COVID-19 vaccine. Interim recommendations for the use of Pfizer-BioNTech COVID-19 Use Authorization (EUA) for Moderna COVID-19 vaccine.
Interim recommendations for the use of Moderna COVID-19 vaccine.
Recommendation on the use of Ebola vaccine. Recommended immunization schedules for children and adolescents, Use Authorization (EUA) for Janssen (Johnson and Johnson) COVID-19 Interim recommendations for the use of Janssen (Johnson and
A CDC Health Alert Network (HAN) was issued with Recommended a pause in use of the Janssen (Johnson & Johnson)ĬOVID-19 vaccine in the United States out of an abundance ofĬaution. EUA fact sheets for Johnson & Johnson (Janssen) Recommended pause of use of Johnson & Johnson (Janssen) COVID-19 Recommendation from ACIP for Use of Janssen (Johnson & Johnson)ĬOVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Recommendations for use of Pfizer-BioNTech COVID-19 Vaccine inĮmergency use authorization of Pfizer-BioNTech COVID-19 vaccine to The suggested increased risks of myocarditis and pericarditisĢ0 (Pfizer) pneumococcal 20-valent conjugate vaccine for adults 18 (Pfizer and Moderna) patient and provider fact sheets regarding Of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Guillain-Barré syndrome (GBS) warning and revising Sheets for Janssen COVID-19 Vaccine (Johnson & Johnson), adding Vaxneuvance (Merck & Co, Inc.) pneumococcal 15-valent conjugate Immunodeficiency or immunosuppression caused by known disease or Older who are or will be at increased risk of zoster due to Indication of Shingrix vaccine to include adults aged 18 years and Moderna COVID-19 vaccines to allow for use of additional dose in Vaccine in individuals 1 year of age and older.Įmergency use authorizations (EUAs) for Pfizer-BioNTech and (Pfizer) a vaccine to prevent tick-borne encephalitis (TBE) (The EUA remains in effect for individuals 12 years ofĪge and older and for third dose for immunocompromised individuals You know of an event that you would like us to add, contact us at and related notesįDA authorizes booster dose of Pfizer-BioNTech COVID-19 Vaccine for aged 65 years and older, aged 18 through 64 at high risk of severe COVID-19, aged 18 through 64 who have institutional or occupational exposure to SARS-CoV-2ĬDC released ACIP recommendations on use of influenza vaccines for the 2021–22 influenza seasonĬOVID-19 vaccine Comirnaty (Pfizer-BioNTech) for individuals 16Īnd older. Immunization-related events that have occurred since Jenner's criticalĭiscovery. The chart which follows displays many of the vaccine- and Slow rate until the last several decades when new scientific discoveries and technologies led to rapid advances in virology, molecular biology, and vaccinology. The development of vaccines continued at a fairly Historic Dates and Events Related to Vaccines and ImmunizationĬelebrated the 200th anniversary of Edward Jenner's first smallpox